Irvine Pharmaceutical Services Completes Successful FDA Inspection

News provided by

Apr 17, 2012, 11:07 ET

IRVINE, Calif., April 17, 2012 /PRNewswire/ --Irvine Pharmaceutical Services, a leading provider of cGMP contract development and manufacturing services for the pharmaceutical, biotech, and medical device industries since 1988, is pleased to announce it successfully completed a five day cGMP audit. This comes as a result of Irvine's 24 years ongoing commitment to the highest levels of quality standards.

Dr. Assad J. Kazeminy, CEO and Founder of Irvine Pharmaceutical Services commented, "Successfully completing a five day audit with three inspectors in which no Form 483 was issued highlights our keen focus on consistently enhancing our quality systems while expanding our scientific expertise and experience. This endorsement provides our clientele with an even higher level of confidence in our partnership."

The team of FDA investigators performed a thorough and comprehensive audit, reviewing data from areas such as analytical development, analytical quality control, stability storage and testing, analytical development, biopharmaceutical development, structural chemistry, drug delivery device technologies, and microbiology.

Learn more about Irvine at www.irvinepharma.com or meet with members of Irvine's team at the following upcoming meetings: 2012 PDA Annual Meeting, TIDES 2012, 2012 AAPS National Biotechnology Conference, and 2012 BIO International Conference.

About Irvine
Founded in 1988, Irvine Pharmaceutical Services is a premier contract pharmaceutical development organization supporting the pharmaceutical, biopharmaceutical, and medical device industries. Irvine offers complete cGMP product development support and dedicated project management including services such as analytical chemistry, analytical development, biopharmaceutical development, structural chemistry, microbiology, stability storage and testing, and drug delivery technologies. Irvine's wholly-owned subsidiary, Avrio Biopharma, also supports the industry providing cGMP formulation development, lyophilization, and aseptic fill-and-finish services.